MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the following upcoming investor conferences:
Baird’s 2017 Global Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 12:15 PM ET
Location: New York, NY
Morgan Stanley 15th Annual Global Healthcare Conference
Date: Tuesday, September 12, 2017
Time: 3:30 PM ET
Location: New York, NY
Live webcasts of the presentations can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. Archived replays will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
